Strengthening Its Position in Global Markets
Santa Farma, a 100% domestically owned pharmaceutical company, has marked a significant milestone in its global brand journey by being accepted into the TURQUALITY Support Program. Founded in 1944 in Edirnekapı and currently managed by the third generation, the company continues to operate with the vision of becoming a reference company that combines local needs in global markets with international standards in healthcare.
With a modern manufacturing facility spanning 40,000 square meters within an 80,000-square-meter site and an R&D center approved by the Turkish Ministry of Health, Santa Farma aims to further enhance its position in international markets through the TURQUALITY program. The company plans to more effectively position its broad expertise, ranging from acute treatments to cardiometabolic diseases, along with its pioneering role in introducing Türkiye’s first biotechnological drug, on the global stage.
A Five-Year Roadmap for Sustainable Growth
The five-year “Development Roadmap” prepared under the program is expected to elevate the strategic partnerships initiated in Europe in 2020 and accelerate the company’s international expansion plans. This process is set to provide strategic momentum to Santa Farma’s vision of aligning local healthcare needs with global standards.
Santa Farma CEO Sami Kiresepi commented on the achievement:
“Our journey began more than 80 years ago with our promise to ‘serve health in a healthy way,’ and that promise continues to guide us today. Being accepted into the TURQUALITY program reflects the global recognition of the ethical values we have carefully upheld for three generations and our manufacturing strength. With the visionary support offered by this program, we are combining the knowledge rooted in our homeland with our international growth strategies. We are closer than ever to our goal of making Santa Farma a reference company symbolizing trust and science in global markets.”
